格隆汇3月18日丨绿竹生物-B(02480.HK)公布年度业绩,截至2024年12月31日止年度,集团其他收入为人民币2138.7万元,同比增长6.5%;年内亏损及全面开支总额为人民币1.68亿元,亏损同比收窄32.5%。截至2024年12月31日止年度,集团继续专注于核心产品LZ901的研发工作。LZ901在中国的III期临床试验的受试者入组已于2024年1月完成,共计26,000名40岁及以上...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.